Bruker (NASDAQ:BRKR) VP Sells $98,400.00 in Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Mark Munch also recently made the following trade(s):

• On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00.

Bruker Stock Down 2.2%

Shares of BRKR opened at $48.39 on Monday. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $61.01. The firm’s 50 day moving average is $47.19 and its 200-day moving average is $40.03. The stock has a market capitalization of $7.35 billion, a PE ratio of -302.44, a P/E/G ratio of 6.24 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The business had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio is -125.00%.

Institutional Trading of Bruker

A number of hedge funds have recently made changes to their positions in BRKR. Vaughan Nelson Investment Management L.P. raised its holdings in Bruker by 71.2% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after purchasing an additional 537,845 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Bruker by 35.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock worth $1,717,000 after buying an additional 10,624 shares during the period. Public Employees Retirement System of Ohio raised its stake in Bruker by 60.8% during the second quarter. Public Employees Retirement System of Ohio now owns 55,672 shares of the medical research company’s stock worth $2,294,000 after buying an additional 21,043 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in Bruker by 39.0% in the second quarter. State of New Jersey Common Pension Fund D now owns 51,828 shares of the medical research company’s stock valued at $2,135,000 after buying an additional 14,547 shares during the period. Finally, Buckhead Capital Management LLC boosted its position in Bruker by 74.2% during the second quarter. Buckhead Capital Management LLC now owns 59,348 shares of the medical research company’s stock valued at $2,445,000 after acquiring an additional 25,288 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research analyst reports. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a report on Wednesday, December 10th. Wells Fargo & Company upped their price objective on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Guggenheim lifted their target price on Bruker from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, Redburn Partners set a $60.00 target price on Bruker in a research note on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $53.36.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.